中文摘要：

目的研究小鼠体内干粉吸人麦胚凝集素（WGA）化修饰的昔萘酸沙美特罗（SalX）纳米粒-微粒（NiMS）的药效学及药动学。方法通过皮下和腹腔注射卵清蛋白（OVA）建立小鼠肺哮喘病理模型，经气道干粉吸人给予WGA-SalX—NiMS粉末，采用对照实验法，检测给药后的肺组织及气道炎症情况，并对药物在小鼠血浆和肺组织中的药代动力学行为进行研究。数据用SigmaState统计软件包处理。结果与模型组相比，SalX—NiMS组和WGA—SalX—NiMS组小鼠支气管肺泡灌洗液（BALF）中自细胞总数、嗜酸粒细胞、淋巴细胞及巨噬细胞数目呈下降趋势。WGA—SalX-NiMS组小鼠BALF中淋巴细胞及巨噬细胞数与SalX—NiMS组相比减少（P〈O．05）。在小鼠血浆中，SalX—NiMS组的tmax为1．500h，Cmax为57．366mg／L，t1，2日为69．315h，AUCmax为2427．205mg·L^-1h，MRT00-00为55．294h；WGA-SalX—NiMS组的tmax为1．000h，Cmax为62．581mg／L，t1，2日为69．315h，AUC。为4071．838mg·L^-1·h，MRT。为75．094h^-1在小鼠肺组织中，SalX—NiMS组的tmax为0．083h，Cmax为0．497μg／mg，t1／2B为11．231h，AUCo-00为3．936,ug·mg。·h，MRT0-∞为13．854h；WGA-SalX—NiMS组的tmax为0．083h，Cmax为0．796μg／mg，tl／2日为27．294h，AUCm为5．578肛g·mg^-1·h，MRTo为26．330h。WGA-SalX-NiMS组的血浆及肺组织药物浓度均高于SalX—NiMS组（P〈O．05）。结论WGA修饰后的SalX-NiMS在小鼠体内易于释药，血浆和肺组织中药物浓度较高，有利于哮喘发作时炎症的控制与改善。

英文摘要：

Objective To study the pharmacodynamics and pharmacokinetics of inhaled dry powder of nanoparticles-in- microparticles system （NiMS） loaded with wheat germ agglutinin （WGA）-anchored salmeterol xinafoate （SalX） in mice. Methods The asthma model was established by subcutaneous and intraperitoneal injection of ovalbumin （OVA） in mice. WGA- SalX-NiMS powder was delivered to mice through airway dry powder inhalation. Reference method was applied in this study. The lung tissue and airway inflammation were examined, and the pharmacokinetics of SalX in the plasma and lung tissue of mice were studied after the administration of WGA-SalX-NiMS. The concentration-time data was analyzed using Sigma State statistical package. Results Compared with the model group, the counts of white cells, eosinophils, lymphocytes and macrophages in the bronchoalveolar lavage fluid （BALF） of mice in SalX-NiMS group and WGA-SalX-NiMS group showed a descending trend. The t3ALF counts of lymphocytes and macrophages in WGA-SalX-NiMS group were significantly less than those in SalX-NiMS group （P〈0.05）. The plasma pharmacokinetics parameters of mice were as follows： tmax 1. 500 h, Cmax 57. 366 mg/L, tl/213 69. 315 h, AUC0-00 2 427. 205 mg · L^-1 · h, MRT0 co 55. 294 h for SalX-NiMS; t 1. 000 h, C 62. 581 mg/L, t1/2β 69. 315 h, AUCo-∞ 4 071. 838 parameters h, MRT0-∞, of lung tissue of mice were mg- lows ： 13. 854 h for SalX-NiMS; tmax 0. 083 L^-1 h, MRT0 75. 094 h for WGA-SalX NiMS. The pharmacokinetics tmax 0. 083 h, C 0. 497 μg/mg, t,/2o 11. 231 h, AUC0α, 3. 936 tLg· mg^-1 . , C 0. 796 μg/mg, t1/2β 27. 294 h, AUCo-∞ 5. 578 μg · mg ^-1 h, MRT0 26. 330 h for WGA-SalX-NiMS. The drug concentrations of WGA SalX-NiMS in both plasma and lung tissue were significantly higher than those of SalX-NiMS （P〈0. 05）. Conclusion The drug release rate of SalX NiMS is promoted and the drug concentrations in the plasma and lung tissue are increased after the modification with WGA, which contributes to the control an